Complete financial analysis of Cybin Inc. (CYBN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cybin Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The Weir Group PLC (WEIGF) Income Statement Analysis – Financial Results
- MBB SE (MBB.DE) Income Statement Analysis – Financial Results
- Amniotics AB (publ) (AMNI.ST) Income Statement Analysis – Financial Results
- Galan Lithium Limited (GLNLF) Income Statement Analysis – Financial Results
- Rohto Pharmaceutical Co.,Ltd. (4527.T) Income Statement Analysis – Financial Results
Cybin Inc. (CYBN)
About Cybin Inc.
Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to treat neuroinflammation. It has also developed EMBARK, a psychedelic-assisted psychotherapy. The company is headquartered in Toronto, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 864.00K | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 424.00K | 251.00K | 168.00K | 664.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -424.00K | -251.00K | -168.00K | 200.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 23.15% | 0.00% | 0.00% | 0.00% |
| Research & Development | 32.36M | 26.15M | 17.59M | 3.30M | 321.60K | 0.00 | 0.00 |
| General & Administrative | 29.80M | 24.49M | 44.79M | 22.48M | 1.36M | 0.00 | 0.00 |
| Selling & Marketing | 2.79M | 881.00K | 1.47M | 4.95M | 117.60K | 0.00 | 0.00 |
| SG&A | 46.47M | 25.37M | 46.25M | 27.42M | 1.63M | 80.52K | 127.22K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -482.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 78.84M | 51.52M | 63.84M | 30.72M | 1.94M | 80.52K | 127.22K |
| Cost & Expenses | 78.84M | 51.52M | 63.84M | 31.39M | 1.94M | 80.52K | 127.22K |
| Interest Income | 619.00K | 603.00K | 241.00K | 60.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 241.00K | 10.00K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 260.00K | 251.00K | 168.00K | 49.00K | 1.95M | 161.14K | 0.00 |
| EBITDA | -78.58M | -51.29M | -63.67M | -32.16M | 9.60K | -80.52K | -127.22K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -3,520.25% | 0.00% | 0.00% | 0.00% |
| Operating Income | -78.84M | -54.94M | -63.60M | -30.46M | -1.95M | -80.52K | -127.22K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -3,525.93% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 756.00K | 4.03M | -3.79M | -1.19M | 9.60K | -20.00K | 4.00 |
| Income Before Tax | -78.08M | -47.49M | -67.63M | -32.22M | -1.94M | -100.52K | -127.22K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -3,729.17% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -7.45M | 3.79M | 10.00K | 9.60 | -161.14K | 0.00 |
| Net Income | -78.08M | -40.04M | -71.42M | -32.22M | -1.94M | -100.52K | -127.22K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -3,729.17% | 0.00% | 0.00% | 0.00% |
| EPS | -9.50 | -0.22 | -0.43 | -0.32 | -0.05 | -0.01 | -0.01 |
| EPS Diluted | -9.41 | -0.22 | -0.43 | -0.32 | -0.04 | -0.01 | -0.01 |
| Weighted Avg Shares Out | 8.22M | 185.43M | 167.29M | 100.01M | 40.50M | 13.89M | 13.89M |
| Weighted Avg Shares Out (Dil) | 8.30M | 185.43M | 167.29M | 100.01M | 49.98M | 13.89M | 13.89M |
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer,...
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced unprecedented 12-month efficacy data from its Phase 2 study...
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that it will host a conference call and...
Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the initiation of PARADIGMTM, its Phase 3 pivotal program...
Cybin to Participate at the 2024 Milken Institute Future of Health Summit
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that Doug Drysdale, Cybin's Chief Executive Officer, will...
Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry platform company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that the United States Patent and Trademark Office...
Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +
The 'Undercovered' Dozen highlights 12 lesser-covered stocks from October 11th - 17th, aiming to inspire discussion and provide investment ideas. AST SpaceMobile is highly volatile but has strong potential in satellite broadband services according to Josh Arnold who initiated a...
Cybin: Top Value Psychedelic Stock
Cybin is a promising value investment, with advanced clinical trials and strong institutional support, poised to disrupt mental health treatment. Cybin's proprietary drugs, CYB003 for depression and CYB004 for anxiety, show groundbreaking efficacy and shorter treatment time, enhancing patient and...
Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce that Doug Drysdale, Cybin's Chief Executive Officer,...
Cybin Expands Clinical Team to Support CYB003 Phase 3 Program
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced the appointment of senior clinical team leaders, Dr. Mirza...
Source: https://incomestatements.info
Category: Stock Reports